NCT06389877View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

August 31, 2027

Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
DRUG

BEAM-302

BEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD

Trial Locations (6)

Unknown

RECRUITING

Clinical Study Center, Adelaide

RECRUITING

Clinical Study Center, Fitzroy

RECRUITING

Clinical Study Center, Leiden

RECRUITING

Clinical Study Center, Auckland

RECRUITING

Clinical Study Center, Hamilton

RECRUITING

Clinical Study Center, London

Sponsors
All Listed Sponsors
lead

Beam Therapeutics Inc.

INDUSTRY

NCT06389877 - A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) | Biotech Hunter | Biotech Hunter